Novartis’ Cosentyx (secukinumab) has failed to show any benefit in the Phase III study in adults with newly diagnosed or ...

Novartis announced top-line results from the phase III GCAptAIN study evaluating Cosentyx (secukinumab) in adults with newly diagnosed or relapsing giant cell arteritis (GCA). In the study, Cosentyx ...

“While the phase 3 results of GCAptAIN did not replicate the positive outcomes observed in the phase 2 trial, we remain committed to continuing to drive scientific progress and deepening the ...

NVS' Cosentyx fails to meet its primary goal in a phase III study for giant cell arteritis, despite favorable safety data.

Swiss pharma giant Novartis has announced top-line results from the Phase III GCAptAIN study evaluating Cosentyx (secukinumab ...

Novartis' blockbuster immunology drug Cosentyx has disappointed in a phase 3 trial involving patients with giant cell ...

Novartis today announced top-line results from the Phase III GCAptAIN study evaluating Cosentyx® (secukinumab) in adults with newly diagnosed or relapsing giant cell arteritis (GCA).

Both regulatory-approved and pipeline treatments for moderate to severe hidradenitis suppurativa demonstrate comparable ...

Secukinumab, an anti-IL-17A monoclonal antibody biologic drug, showed promise as a treatment for patients with active ankylosing spondylitis, according to new research. Ankylosing spondylitis, or ...

Secukinumab treatment was associated with lower odds of enthesophyte progression (odds ratio [OR], 0.264; P = .030) and higher odds of partial healing of erosion (OR, 2.882; P = .027).

The GCAptAIN study did not meet its primary endpoint of sustained remission at Week 52 in adults with newly diagnosed or relapsing GCA1Safety in GCA patients was consistent with known safety profile o ...

Corticosteroids, commonly used in SLE, can exacerbate psoriasis, while phototherapy for psoriasis may trigger lupus flares. In this case, secukinumab, an IL-17A inhibitor, provided effective control ...